Использование белковых и пептидных векторов для избирательной доставки противоопухолевых препаратов и терапевтических олигонуклеотидов в опухолевые клетки
Диссертация
Необходимо отметить особую важность при конструировании САД выбора линкера, связывающего векторный белок с цитотоксическим агентом. Цитостатик может быть успешно доставлен в клетку-мишень, но если не обеспечить своевременное его отщепления от вектора, биологический эффект реализован либо не будет, либо будет слабо выражен. Анализ эффективности конъюгатов АФП с ДОКС, в которых были использованы… Читать ещё >
Список литературы
- Jain R.K. Delivery of molecular and cellular medicine to solid tumors. // Adv Drug Deliv Rev. 2001. V. 46. № 1−3. P. 149−168.
- Jang S.H., Wientjes M.G., Lu D., Au J.L. Drug delivery and transport to solid tumors. // Pharm Res. 2003. V. 20. № 9. P. 1337−1350.
- Grillo-Lopez A.J., White C.A., Varns C., Shen D., Wei A., McClure A., Dallaire B.K. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. // Semin Oncol. 1999. V. 26. № 5 Suppl 14. P. 66−73.
- Huhn D., von Schilling C" Wilhelm M" Ho A.D., Hallek M., Kuse R, Knauf W" Riedel U., Hinke A., Srock S., Serke S., Peschel C., Emmerich B. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. // Blood. 2001. V. 98. № 5. P. 1326−1331.
- Gribben J.G., Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. //Br J Haematol. 2009. V. 144. № 6. P. 818−831.
- Ravandi F., O’Brien S. Alemtuzumab in CLL and other lymphoid neoplasms. // Cancer Invest. 2006. V. 24. № 7. P. 718−725.
- Alinari L., Lapalombella R., Andritsos L., Baiocchi R.A., Lin T.S., Byrd J.C. Alemtuzumab (Campath-IH) in the treatment of chronic lymphocytic leukemia. // Oncogene. 2007. V. 26. № 25. P. 3644−3653.
- Baselga J. A review of EGFR targeted therapy. // Clin Adv Hematol Oncol. 2003. V. 1. № 4. P. 218−219.
- Fischgrabe J., Wulfing P. Targeted therapies in breast cancer: established drugs and recent developments. // Curr Clin Pharmacol. 2008. V. 3. № 2. P. 85−98.
- Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. // Clin Ther. 1999. V. 21. № 2. P. 309−318.
- Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. // Science. 1987. V. 235. № 4785. P. 177−182.
- Azim H., Azim H.A., Jr. Targeting Her-2/neu in breast cancer: as easy as this! // Oncology. 2008. V. 74. № 3−4. P. 150−157.
- Albanell J., Codony J., Rovira A., Mellado В., Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. // Adv Exp Med Biol. 2003. V. 532. P.253−268.
- Stern M., Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. // Crit Rev Oncol Hematol. 2005. V. 54. № 1. P. 11−29.
- Gutheil J. The promise of monoclonal antibodies for the therapy of cancer. // Crit Rev Oncol Hematol. 2001. V. 38. № 1. P. 1−2.
- Моисеенко B.M. Моноклональные антитела в лечении злокачественных опухолей. // Практическая онкология. 2003. V. 4. № 3. Р. 148−156.
- Guillemard V., Uri Saragovi Н. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. // Oncogene. 2004. V. 23. № 20. P. 3613−3621.
- Ricart A.D., Tolcher A.W. Technology Insight: cytotoxic drug immunoconjugates for cancer therapy. // Nat Clin Prac Oncol. 2007. V. 4. № 4. P. 245−255.
- Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., Forero-Torres A. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. // New England Journal of Medicine. V. 363. № 19. P. 1812−1821.
- Krop I.E., Beeram M., Modi S., Jones S.F., Holden S.N., Yu W., Girish S., Tibbitts J., Yi J.-H., Sliwkowski M.X., Jacobson F., Lutzker S.G., Burris H.A. Phase I Study of Trastuzumab
- DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. // Journal of Clinical Oncology. V. 28. № 16. P. 2698−2704.
- Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. // Expert Opin Biol Ther. 2008. V. 8. № 4. P. 527−540.
- Tsimberidou A.M., Giles F.J., Estey E., O’Brien S., Keating M.J., Kantarjian H.M. The role of gemtuzumab ozogamicin in acute leukaemia therapy. // Br J Haematol. 2006. V. 132. № 4. P. 398−409.
- Gao Z., McAlister V.C., Williams G.M. Repopulation of liver endothelium by bone-marrow-derived cells. // Lancet. 2001. V. 357. № 9260. P. 932−933.
- Zein N., Sinha A.M., McGahren W.J., Ellestad G.A. Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. // Science. 1988. V. 240. № 4856. P. 1198−1201.
- Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. // Adv Cancer Res. 2001. V. 81. P. 93−124.
- Goyal A., Batra J.K. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. // Biochem J. 2000. V. 345 Pt 2. P. 247−254.
- Kreitman R.J. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. // BioDrugs. 2009. V. 23. № 1. P. 1−13.
- Jain R.K., Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. // Cancer Res. 1988. V. 48. № 24 Pt 1. P. 7022−7032.
- Green M.C., Murray J.L., Hortobagyi G.N. Monoclonal antibody therapy for solid tumors. // Cancer Treat Rev. 2000. V. 26. № 4. P. 269−286.
- Brada M. BCL2 gene: current relevance to clinical oncology. // Eur J Cancer. 1992. V. 28. № 1. P. 270−272.
- Yip K.W., Reed J.C. Bcl-2 family proteins and cancer. // Oncogene. 2008. V. 27. № 50. P. 6398−6406.
- Reed J.C. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. // Adv Pharmacol. 1997. V. 41. P. 501−532.
- Reed J.C. Bel-2 family proteins: regulators of chemoresistance in cancer. // Toxicol Lett. 1995. V. 82−83. P. 155−158.
- Tarhini A.A., Kirkwood J.M. Oblimersen in the treatment of metastatic melanoma. // Future Oncol. 2007. V. 3. № 3. P. 263−271.
- Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide Genta, G 3139, GC 3139, oblimersen sodium. // Drugs R D. 2007. V. 8. № 5. P. 321−334.
- Manoharan M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. /'/ Antisense Nucieic Acid Drug Dev. 2002. V. 12. № 2. P. 103−128.
- Abels C. Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). // Photochem Photobiol Sci. 2004. V. 3. № 8. P. 765−771.
- Nowis D., Makowski M., Stoklosa T., Legat M., Issat T., Golab J. Direct tumor damage mechanisms of photodynamic therapy. // Acta Biochim Pol. 2005. V. 52. № 2. P. 339−352.
- Robertson C.A., Evans D.H., Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. // J Photochem Photobiol B. 2009. V. 96. № 1. P. 1−8.
- Aveline B.M., Redmond R.W. Exclusive Free Radical Mechanisms of Cellular Photosensitization. // Photochemistry and Photobiology. 1998. V. 68. № 3. P. 266−275.
- Henderson B.W., Dougherty T.J. How does photodynamic therapy work? // Photochem Photobiol. 1992. V. 55. № 1. P. 145−157.
- Cahill M.T., Smith B.T., Fekrat S. Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (visudyne). // Am J Ophthalmol. 2002. V. 134. № 2. P. 281−282.
- Cheng Y., A C.S., Meyers J.D., Panagopoulos I., Fei B., Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. // J Am Chem Soc. 2008. V. 130. № 32. P. 10 643−10 647.
- Sharman W.M., van Lier J.E., Allen C.M. Targeted photodynamic therapy via receptor mediated delivery systems. // Adv Drug Deliv Rev. 2004. V. 56. № 1. P. 53−76.
- Oleinick N.L., Evans H.H. The photobiology of photodynamic therapy: cellular targets and mechanisms. // Radiat Res. 1998. V. 150. № 5 Suppl. P. S146−156.
- Rosenkranz A.A., Jans D.A., Sobolev A.S. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. // Immunol Cell Biol. 2000. V. 78. № 4. P. 452−464.
- Rozanova Torshina N., Zhang J.Z., Heck D.E. Catalytic therapy of cancer with porphyrins and ascorbate. // Cancer Lett. 2007. V. 252. № 2. P. 216−224.
- Хорошева Е.В., Герасимова Г. К., Калия O.J1. Изучение механизма транспорта терафтала в опухолевые клетки
- Российский биотерапевтический журнал 2007. V. 6. № 1. Р. 8.
- Кульбачевская Н.Ю., Манзюк Л. В., Михайлова JI.M. Клинико-экспериментальное изучение токсичности противоопухолевой каталитической системы «терафтал+аскорбиновая кислота» («ТФ+АК»). // Российский биотерапевтический журнал. 2004. V. 3. № 2. Р. 70.
- Ravi Kumar M.N. Nano and microparticles as controlled drug delivery devices. // J Pharm Pharm Sci. 2000. V. 3. № 2. P. 234−258.
- Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. // Adv Drug Deliv Rev. 2012. V. P.
- Fu Q., Sun J., Zhang W., Sui X., Yan Z., He Z. Nanoparticle Albumin bound (nab) Technology is a Promising Method for Anti-cancer Drug Delivery. // Recent Pat Anticancer Drim Dkrnv 9ПП9 V P
- Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., Ruoslahti E. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. //Nanomedicine. 2009. V, 5. № 1. P. 73−82.
- Henderson I.C., Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. // Expert Rev Anticancer Ther. 2007. V. 7. № 7. P. 919−943.
- Moreno-Aspitia A., Perez E.A. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. // Future Oncol. 2005. V. 1. № 6. P. 755−762.
- Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. // Advanced drug delivery reviews. 2007. V. 59. № 8. P. 748−758.
- Mousavi S.A., Malerod L., Berg T., Kjeken R. Clathrin-dependent endocytosis. // Biochem J. 2004. V. 377. №Pt l.P. 1−16.
- Rodemer C., Haucke V. Clathrin/AP-2-dependent endocytosis: a novel playground for the pharmacological toolbox? // Handb Exp Pharmacol. 2008. V. № 186. P. 105−122.
- Mousavi S.A., Malerod L., Berg T., Kjeken R. Clathrin-dependent endocytosis. // The Biochemical journal. 2004. V. 377. №Pt 1. P. 1−16.
- Slepnev Y.I., De Camilli P. Accessory factors in clathrin-dependent synaptic vesicle endocytosis. //Nat Rev Neurosci. 2000. V. 1. № 3. P. 161−172.
- Marsh M., McMahon H.T. The structural era of endocytosis. // Science. 1999. V. 285. № 5425. P. 215−220.
- Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. // Adv Drug Deliv Rev. 2007. V. 59. № 8. P. 748−758.
- Hinshaw J.E., Schmid S.L. Dynamin self-assembles into rings suggesting a mechanism for coated vesicle budding. //Nature. 1995. V. 374. № 6518. P. 190−192.
- Ferguson S.M., De Camilli P. Dynamin, a membrane-remodelling GTPase. // Nat Rev Mol Cell Biol. 2012. V. 13. № 2. P. 75−88.
- Aniento F., Emans N., Griffiths G., Gruenberg J. Cytoplasmic dynein-dependent vesicular transport from early to late endosomes. // The Journal of cell biology. 1993. V. 123. № 6 Pt 1. P. 1373−1387.
- Stahl P.D., Barbieri M.A. Multivesicular bodies and multivesicular endosomes: the «ins and outs» of endosomal traffic. // Science’s STKE: signal transduction knowledge environment. 2002. V. 2002. № 141. P. pe32.
- Piper R.C., Luzio J.P. Late endosomes: sorting and partitioning in multivesicular bodies. // Traffic. 2001. V. 2. № 9. P. 612−621.
- Pillay C.S., Elliott E., Dennison C. Endolysosomal proteolysis and its regulation. // The Biochemical journal. 2002. V. 363. №Pt 3. P. 417−429.
- Eskelinen E.-L. Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. // Molecular Aspects of Medicine. 2006. V. 27. № 5−6. P. 495−502.
- Smart E.J., Graf G.A., McNiven M.A., Sessa W.C., Engelman J.A., Scherer P.E., Okamoto T., Lisanti M.P. Caveolins, liquid-ordered domains, and signal transduction. // Mol Cell Biol. 1999. V. 19. № 11. P. 7289−7304.
- Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. // Pharmacol Rev. 2006. V. 58. № 1. P. 32−45.
- Lajoie P., Nabi I.R. Chapter 3 Lipid Rafts, Caveolae, and Their Endocytosis. In: Kwang WJ, editor. International Review of Cell and Molecular Biology: Academic Press- 2010. p. 135 163.
- Damm E.M., Pelkmans L., Kartenbeck J., Mezzacasa A., Kurzchalia T., Helenius A. Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. // J Cell Biol. 2005. V. 168. № 3. P. 477−488.
- Rawat A., Vaidya B., Khatri K., Goyal A.K., Gupta P.N., Mahor S., Paliwal R., Rai S., Vyas S.P. Targeted intracellular delivery of therapeutics: an overview. // Die Pharmazie. 2007. V. 62. № 9. P. 643−658.
- Fenton C., Perry C.M. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. // Drugs. 2005. V. 65. № 16. P. 2405−2427.
- Cang S., Mukhi N., Wang K., Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. // Journal of Hematology & Oncology. 2012. V. 5. № 1. P. 64.
- Chari R.V.J. Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs. // Accounts of Chemical Research. 2007. V. 41. № 1. P. 98−107.
- Casi G., Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. // Journal of controlled release: official journal of the Controlled Release Society. 2012. V. 161. № 2. P. 422−428.
- Uckun F.M., Narla R.K., Jun X., Zeren Т., Venkatachalam Т., Waddick K.G., Rostostev A., Myers D.E. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. // Clin Cancer Res. 1998. V. 4. № 4. P. 901−912.
- Rihova B. Targeting of Drugs to Cell Surface Receptors. // Critical Reviews in Biotechnology. 1997. V. 17. № 2. P. 149−169.
- Jaracz S., Chen J., Kuznetsova L.V., Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. // Bioorganic & medicinal chemistry. 2005. V. 13. .№ 17. P. 50 435 054.
- Bildstein L., Dubernet C., Couvreur P. Prodrug-based intracellular delivery of anticancer agents. // Advanced drug delivery reviews. 2011. V. 63. № 1−2. P. 3−23.
- Singh Y., Palombo M., Sinko P.J. Recent trends in targeted anticancer prodrug and conjugate design. // Current medicinal chemistry. 2008. V. 15. № 18. P. 1802−1826.
- Sanderson R.J., Hering M A., James S.F., Sun M.M., Doronina S.O., Siadak A.W., Senter P.D., Wahl A.F. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. // Clin Cancer Res. 2005. V. 11. № 2 Pt 1. P. 843−852.
- Krippendorff B.F., Kuester K., Kloft C., Huisinga W. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. // J Pharmacokinet Pharmacodyn. 2009. V. 36. № 3. P. 239−260.
- Malyankar U.M. Tumor-associated antigens and biomarkers in cancer and immune therapy. // Int Rev Immunol. 2007. V. 26. № 3−4. P. 223−247.
- Тюряева И.И. Опухолевые антигены. // Цитология. 2008. V. 50. № 3. Р. 189−209.
- Duffour M.T., Chaux P., Lurquin C., Cornells G., Boon Т., van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. // Eur J Immunol. 1999. V. 29. № 10. P. 3329−3337.
- Houghton A.N. Cancer antigens: immune recognition of self and altered self. // J Exp Med. 1994. V. 180. № 1. P. 1−4.
- Carubia J.M., Yu R.K., Macala L.J., Kirkwood J.M., Varga J.M. Gangliosides of normal and neoplastic human melanocytes. // Biochem Biophys Res Commun. 1984. V. 120. № 2. P. 500−504.
- Tang C.K., Katsara M., Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. // Expert Rev Vaccines. 2008. V. 7. № 7. P. 963−975.
- Casalini P., Iorio M.V., Galmozzi E., Menard S. Role of HER receptors family in development and differentiation. //J Cell Physiol. 2004. V. 200. № 3. P. 343−350.
- Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. // EMBO J. 2000. V. 19. № 13. P. 3159−3167.
- Барышников А.Ю. Взаимоотношение опухоли и иммунной системы организма. // Практическая онкология. 2003. V. 4. № 3. Р. 127−130.
- Wang D., Rayani S., Marshall J.L. Carcinoembryonic antigen as a vaccine target. // Expert Rev Vaccines. 2008. V. 7. № 7. P. 987−993.
- Singer J.W., De Vries P., Bhatt R, Tulinsky J., Klein P., Li C., Milas L., Lewis R.A., Wallace S. Conjugation of camptothecins to poly-(L-glutamic acid). // Ann N Y Acad Sci. 2000. V. 922. P.136−150.
- Nicolay K., Fok J.J., Voorhout W. Post LA, de Kruijff B. Cytofluorescence detection of adriamycin-mitochondria interactions in isolated, perfused rat heart. // Biochim Biophys Acta. 1986. V. 887. № 1. P. 35−41.
- Evdokimova V.N., Butterfield L.H. Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. // Expert Opin Biol Ther. 2008. V. 8. № 3. P. 325 336.
- Abelev G.I., Eraiser T.L. Cellular aspects of alpha-fetoprotein reexpression in tumors. // Semin Cancer Biol. 1999. V. 9. № 2. P. 95−107.
- Mizejewski G.J. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. // Exp Biol Med (Maywood). 2001. V. 226. № 5. P. 377−408.
- Castelli C., Rivoltini L., Andreola G., Carrabba M., Renkvist N., Parmiani G. T-cell recognition of melanoma-associated antigens. // J Cell Physiol. 2000. V. 182. № 3. P. 323−331.
- Van den Eynde B., Peeters O., De Backer O., Gaugier B., Lucas S., Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. // J Exp Med. 1995. V. 182. № 3. P. 689−698.
- Lewis J. J., Houghton A.N. Definition of tumor antigens suitable for vaccine construction. // Semin Cancer Biol. 1995. V. 6. № 6. P. 321−327.
- Deprez-de Campeneere D., Masquelier M., Baurain R., Trouet A. Drug targeting in cancer treatment: active daunorubicin-protein conjugates. // Prog Clin Biol Res. 1982. V. 102 pt A. P. 291−298.
- Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. // J Control Release. 2000. V. 65. № 1−2. P. 271−284.
- Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. // Jpn J Cancer Res. 1998. V. 89. № 3. P. 307−314.
- Kratz F., Beyer U. Serum proteins as drug carriers of anticancer agents: a review. // Drug Deliv. 1998. V. 5. № 4. P. 281−299.
- Kratz F., Beyer U., Collery P., Lechenault F., Cazabat A., Schumacher P., Falken U., Unger C. Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin. // Biol Pharm Bull. 1998. V. 21. № 1. P. 56−61.
- Kratz F., Beyer U, Roth T., Schutte M.T., Unold A., Fiebig H.H., Unger C. Albumin conjugates of the anticancer drug chlorambucil: synthesis, characterization, and in vitro efficacy. // Arch Pharm (Weinheim). 1998. V. 331. № 2. P. 47−53.
- Association for Medical Oncology of the German Cancer Society. // Clin Cancer Res. 1999. V. 5. № 4. P. 753−759.
- Warnecke A., Fichtner I., Sass G., Kratz F. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. // Arch Pharm (Weinheim). 2007. V. 340. № 8. P. 389−395.
- Kratz F., Drevs J., Bing G., Stockmar C., Scheuermann K., Lazar P., Unger C. Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates. // Bioorg Med Chem Lett. 2001. V. 11. № 15. P. 2001−2006.
- Kratz F., Beyer U., Schutte M.T. Drug-polymer conjugates containing acid-cleavable bonds. // Crit Rev Ther Drug Carrier Syst. 1999. V. 16. № 3. P. 245−288.
- Kratz F., Warnecke A., Schmid B., Chung D.E., Gitzel M. Prodrugs of anthracyclines in cancer chemotherapy. // Curr Med Chem. 2006. V. 13. № 5. P. 477−523.
- Unger C., Haring B., Medinger M., Drevs J., Steinbild S., Kratz F., Mross K. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. // Clin Cancer Res. 2007. V. 13. № 16. P. 4858−4866.
- Kratz F., Mansour A., Soltau J., Warnecke A., Fichtner I., Unger C., Drevs J. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. // Arch Pharm (Weinheim). 2005. V. 338. № 10. P. 462−472.
- Abu Ajaj K., Graeser R., Fichtner I., Kratz F. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. // Cancer Chemother Pharmacol. 2009. V. 64. № 2. P. 413−418.
- Ajaj K.A., Biniossek M.L., Kratz F. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs. // Bioconjug Chem. 2009. V. 20. № 2. P. 390−396.
- Abu Ajaj K., Kratz F. Development of dual-acting prodrugs for circumventing multidrug resistance. // Bioorg Med Chem Lett. 2009. V. 19. № 3. P. 995−1000.
- Dautry-Varsat A. Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor. // Biochimie. 1986. V. 68. № 3. P. 375−381.
- Daniels T.R., Delgado T., Rodriguez J.A., Helguera G., Penichet M.L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. // Clin Immunol. 2006. V. 121. № 2. P. 144−158.
- Gomme P.T., McCann K.B., Bertolini J. Transferrin: structure, function and potential therapeutic actions. // Drug Discov Today. 2005. V. 10. № 4. P. 267−273.
- Singh M., Atwal H., Micetich R. Transferrin directed delivery of adriamycin to human cells. // Anticancer Res. 1998. V. 18. № 3A. P. 1423−1427.
- Berczi A., Barabas K., Sizensky J.A., Faulk W.P. Adriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cells. // Arch Biochem Biophys. 1993. V. 300. № 1. P. 356−363.
- Sun I.L., Sun E.E., Crane F.L., Morre D.J., Faulk W.P. Inhibition of transplasma membrane electron transport by transferrin-adriamycin conjugates. // Biochim Biophys Acta. 1992. V. 1105. № 1. P. 84−88.
- Berczi A., Ruthner M., Szuts V., Fritzer M., Schweinzer E., Goldenberg H. Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. // Eur J Biochem. 1993. V. 213. № 1. P. 427−436.
- Lai B.T., Gao J.P., Lanks K.W. Mechanism of action and spectrum of cell lines sensitive to a doxorubicin-transferrin conjugate. // Cancer Chemother Pharmacol. 1998. V. 41. № 2. P. 155 160.
- Daniels T.R., Delgado T., Helguera G., Penichet M.L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. // Clin Immunol. 2006. V. 121. № 2. P. 159−176.
- Hoshino T., Misaki M., Yamamoto M., Shimizu H., Ogawa Y., Toguchi H. In vitro cytotoxicities and in vivo distribution of transferrin-platinum (II) complex. // J Pharm Sci. 1995. V. 84. № 2. P. 216−221.
- Elliott R.L., Stjernholm R., Elliott M.C. Preliminary evaluation of platinum transferrin (MPTC-63) as a potential nontoxic treatment for breast cancer. // Cancer Detect Prev. 1988. V. 12. № 1−6. P. 469−480.
- Head J.F., Wang F., Elliott R.L. Antineoplastic drugs thai interfere with iron metabolism in cancer cells. //Adv Enzyme Regul. 1997. V. 37. P. 147−169.
- Beyer U., Roth T., Schumacher P., Maier G., Unold A., Frahm A.W., Fiebig H.H., Unger C., Kratz F. Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil. //J Med Chem. 1998. V. 41. № 15. P. 2701−2708.
- Tanaka T., Shiramoto S., Miyashita M., Fujishima Y., Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). // Int J Pharm. 2004. V. 277. № 1−2. P. 39−61.
- Frankel A.E. Increased sophistication of immunotoxins. // Clin Cancer Res. 2002. V. 8. № 4. P. 942−944.
- Frankel A.E., Neville D.M., Bugge T.A., Kreitman R.J., Leppla S.H. Immunotoxin therapy of hematologic malignancies. // Semin Oncol. 2003. V. 30. № 4. P. 545−557.
- Martell L.A., Agrawal A., Ross D.A., Muraszko K.M. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. // Cancer Res. 1993. V. 53. № 6. P. 1348−1353.
- Weaver M., Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. // J Neurooncol. 2003. V. 65. № 1. P. 3−13.
- Hyer M.L., Sudarshan S., Kim Y., Reed J.C., Dong J.Y., Schwartz D.A., Norris J.S. Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. // Cancer Biol Ther. 2002. V. 1. № 4. P. 401−406.
- Gijsens A., Missiaen L., Merlevede W., de Witte P. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. // Cancer Res. 2000. V. 60. № 8. P. 2197−2202.
- Shimizu N., Shimizu Y., Miskimins W.K. EGF-ricin A conjugates: kinetic profiles of cytotoxic effects and resistant cell variants. // Cell Struct Funct. 1984. V. 9. № 3. P. 203−212.
- Drin G., Mazel M., Clair P., Mathieu D., Kaczorek M., Temsamani J. Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinity. // Eur J Biochem. 2001. V. 268. № 5. P. 1304−1314.
- Vives E., Richard J.P., Rispal C., Lebleu B. TAT peptide internalization: seeking the mechanism of entry. // Curr Protein Pept Sci. 2003. V. 4. № 2. P. 125−132.
- Krauss U., Kratz F., Beck-Sickinger A.G. Novel daunorubicin-carrier peptide conjugates derived from human calcitonin segments. // J Mol Recognit. 2003. V. 16. № 5. P. 280−287.
- Rezler E.M., Bearss D.J., Hurley L.H. Telomere inhibition and telomere disruption as processes for drug targeting. // Annu Rev Pharmacol Toxicol. 2003. V. 43. P. 359−379.
- Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. // Analytical Biochemistry. 1987. V. 162. № 1. P. 156 159.
- Nechushtan A., Yarkoni S., Marianovsky I., Lorberboum-Galski H. Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. // J Biol Chem. 1997. V. 272. № 17. P. 11 597−11 603.
- Liu T.F., Cohen K.A., Ramage J.G., Willingham M.C., Thorburn A.M., Frankel A.E. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. // Cancer Res. 2003. V. 63. № 8. P. 1834−1837.
- Osborne C.K., Coronado-Heinsohn E. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). // Cancer J Sci Am. 1996. V. 2. № 3. P. 175−180.
- Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. // Expert Rev Anticancer Ther. 2007. V. 7. № 1. P. 11−17.
- Wong B.Y., Gregory S.A., Dang N.H. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. // Cancer Invest. 2007. V. 25. № 6. P. 495−501.
- Duvic M., Talpur R. Optimizing denileukin diftitox (Ontak) therapy. // Future Oncol. 2008. V. 4. № 4. P. 457−469.
- Foss F. Clinical experience with denileukin diftitox (ONTAK). // Semin Oncol. 2006. V. 33. № 1 Suppl 3. P. SI 1−16.
- Mavromatis B.H., Cheson B.D. Novel therapies for chronic lymphocytic leukemia. // Blood Rev. 2004. V. 18. № 2. P. 137−148.
- Walker P.L., Dang N.H. Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma. // Clin J Oncol Nurs. 2004. V. 8. № 2. P. 169−174.
- Eklund J.W., Kuzel T.M. Denileukin diftitox: a concise clinical review. // Expert Rev Anticancer Ther. 2005. V. 5. № 1. P. 33−38.
- Black J.H., McCubrey J.A., Willingham M.C., Ramage J., Hogge D.E., Frankel A.E. Diphtheria toxin-interleukin-3 fusion protein (DT (388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. // Leukemia. 2003. V. 17. № 1. P. 155−159.
- Frankel A., Liu J.S., Rizzieri D., Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. // Leuk Lymphoma. 2008. V. 49. № 3. P. 543−553.
- Shimamura T., Husain S.R., Puri R.K. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. // Neurosurg Focus. 2006. V. 20. № 4. P. El 1.
- Therapy with and without Temozolomide in Newly Diagnosed Malignant Gliomas: Phase 1 Study of Final Safety Results. //Neurosurgery. 2008. V. P.
- Jarboe J.S., Johnson K.R., Choi Y., Lonser R.R., Park J.K. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. // Cancer Res. 2007. V. 67. № 17. P. 7983−7986.
- Aqeilan R., Yarkoni S., Lorberboum-Galski H. Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. // FEBS Lett. 1999. V. 457. № 2. P. 271−276.
- Aqeilan R., Kedar R., Ben-Yehudah A., Lorberboum-Galski H. Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor. // Biochem J. 2003. V. 370. №Pt 1. P. 129−140.
- Bergstrand C.G., Czar B. Demonstration of a new protein fraction in serum from the human fetus. // Scand J Clin Lab Invest. 1956. V. 8. № 2. P. 174.
- Абелев Г. И., Перова С.Д., Храмкова Н. И., Постникова З. А., С. И. И. Эмбриональный сывороточный а-глобулин и его синтез перевиваемыми гепатомами мышей. // Биохимия. 1963. V. 28. № 4. Р. 625−634.
- Татаринов Ю.С. Обнаружение эмбриоспецифического а-глобулина в сыворотке крови больного первичным раком печени. // Вопр. мед. химии. 1964. V. 10. Р. 90−91.
- Абелев Г. И., Эльгорт Д. А. Альфа-фетопротеин как иммунологический маркер гепатоцеллюлярного рака и тератокарциномы яичка и яичников. // Онкология. 1978. V. 10. Р. 3−17.
- Brock D.J., Bolton А.Е., Monaghan J.M. Prenatal diagnosis of anencephaly through maternal serum-alphafetoprotein measurement. // Lancet. 1973. V. 2. № 7835. P. 923−924.
- Aitken D.A., Crossley J.A. Neural tube defects/alpha-fetoprotein/Down's syndrome screening. // Curr Opin Obstet Gynecol. 1997. V. 9. № 2. P. 113−120.
- Deutsch H.F. Chemistry and biology of alpha-fetoprotein. // Adv Cancer Res. 1991. V. 56. т" t i nг. zjj-j1z.
- Luft A.J., Lorscheider F.L. Structural analysis of human and bovine alpha-fetoprotein by electron microscopy, image processing, and circular dichroism. // Biochemistry. 1983. V. 22. № 25. P. 5978−5981.
- Johnson P.J., Poon T.C., Hjelm N.M., Ho C.S., Blake С., Ho S.K. Structures of disease-specific serum alpha-fetoprotein isoforms. // Br J Cancer. 2000. V. 83. № 10. P. 1330−1337.
- Parmelee D.C., Evenson M.A., Deutsch H.F. The presence of fatty acids in human alpha-fetoprotein. // J Biol Chem. 1978. V. 253. № 7. P. 2114−2119.
- Urano Y., Sakai M., Watanabe K., Tamaoki T. Tandem arrangement of the albumin and alpha-fetoprotein genes in the human genome. // Gene. 1984. V. 32. № 3. P. 255−261.
- Лазаревич Н.Л. Молекулярные механизмы регуляции экспрессии гена альфа-фетопротеина. // Биохимия. 2000. V. 65. № 1. Р. 139−158.
- Jose-Estanyol М., Danan J.L. A liver-specific factor and nuclear factor I bind to the rat alpha-fetoprotein promoter. // J Biol Chem. 1988. V. 263. № 22. P. 10 865−10 871.
- Crowe A.J., Sang L., Li K.K., Lee K.C., Spear B.T., Barton M.C. Hepatocyte nuclear factor 3 relieves chromatin-mediated repression of the alpha-fetoprotein gene. // J Biol Chem. 1999. V. 274. № 35. P. 25 113−25 120.
- Galarneau L., Pare J., Allard D., Hamel D., Levesque L., Tugwood J., Green S., Belanger L. The alpha 1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. // Mol. Cell. Biol. 1996. V. 16. № 7. P. 3853−3865.
- Shen H., Luan F., Liu H., Gao L., Liang X., Zhang L., Sun W., Ma C. ZHX2 is a repressor of a-fetoprotein expression in human hepatoma cell lines. // Journal of Cellular and Molecular Medicine. 2008. V. 12. № 6b. P. 2772−2780.
- Van Reeth Т., Gabant P., Szpirer C., Szpirer J. Stimulation of the alphaj-feioproiein promoter by unliganded thyroid hormone receptor in association with protein deacetylation. // Molecular and Cellular Endocrinology. 2002. V. 188. № 1−2. P. 99−109.
- Lienard P., De Mees C., Drnze P.L., Dieu M., Dierick J.F., Raes M., Szpirer J., Szpirer C. Regulation of the alpha-fetoprotein promoter: Ku binding and DNA spatial conformation. // Biochimie. 2006. V. 88. № 10. P. 1409−1417.
- Mizejewski G.J. Biological roles of alpha-fetoprotein during pregnancy and perinatal development. // Exp Biol Med (Maywood). 2004. V. 229. № 6. P. 439−463.
- Nishihira J., Koyama Y., Sakai M., Nishi S. The fatty acid binding site of human alpha-fetoprotein. // Biochem Biophys Res Commun. 1993. V. 196. № 3. P. 1049−1057.
- Iturralde M., Alava M.A., Gonzalez B., Anel A., Pineiro A. Effect of alpha-fetoprotein and albumin on the uptake of polyunsaturated fatty acids by rat hepatoma cells and fetal rat hepatocytes. // Biochim Biophys Acta. 1991. V. 1086. № 1. P. 81−88.
- Mizejewski G.J., Pass K.A. Fatty acids, alpha-fetoprotein, and cystic fibrosis. // Pediatrics. 2001. V. 108. № 6. P. 1370−1373.
- Mizejewski G.J., Antelman D.E., Keenan J.F., Preiss I.L. Effects of heavy metals on alpha-fetoprotein in maternal sera and amniotic fluid of pregnant mice. // Toxicology. 1990. V. 64. № 1. P. 19−32.
- Keel B.A., Eddy K.B., He Y., Gangrade B.K., May J.V. Purified human alpha-fetoprotein inhibits follicle-stimulating hormone-stimulated estradiol production by porcine granulosa cells in culture. // Mol Cell Endocrinol. 1993. V. 94. № 1. P. 21−25.
- Mizejewski G.J., Vonnegut M., Jacobson H.I. Estradiol-activated alpha-fetoprotein suppresses the uterotropic response to estrogens. // Proc Natl Acad Sci USA. 1983. V. 80. № 9. P. 2733−2737.
- Jacobson H.I., Bennett J.A., Mizejewski G.J. Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. // Cancer Res. 1990. V. 50. № 2. P. 415−420.
- Mizejewski G.J., Warner A.S. Alpha-fetoprotein can regulate growth in the uterus of the immature and adult ovariectomized mouse. // J Reprod Fertil. 1989. V. 85. № 1. P. 177−185.
- Mizejewski G.J., Vonnegut M., Jacobson H.I. Studies of the intrinsic antiuterotropic activity of murine alpha-fetoprotein. // Tumour biology. 1986. V. 7. № 1. P. 19−36.
- Jacobson H.I., Lemanski N-, Narendran A., .Agarwal A., Bennett J.A., Andersen T.T. Hormones of pregnancy, alpha-feto protein, and reduction of breast cancer risk. // Adv Exp Med Biol. 2008. V. 617. P. 477−484.
- Mizejewski G.J. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. // Expert Rev Anticancer Ther. 2002. V. 2. № 6. P. 709−735.
- Li M.S., Li P.F., He S.P., Du G.G., Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. // World J Gastroenterol. 2002. V. 8. № 3. P. 469−475.
- Li M.S., Li P.F., Yang F.Y., He S.P., Du G.G., Li G. The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells. // Cell Res. 2002. V. 12. № 2. P. 151 156.
- Li M.S., Li P.F., Li G., Du G.G. Enhancement of proliferation of HeLa cells by the alpha-fetoprotein. // Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002. V. 34. № 6. P. 769−774.
- Li M., Li H., Li C., Wang S., Jiang W., Liu Z., Zhou S., Liu X., McNutt M.A., Li G. Alpha-fetoprotein: A new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines. // Int J Cancer. V. P.
- Chakraborty M., Mandal C. Immuno-suppressive effect of human alphafetoprotein: a cross species study. // Immunol Invest. 1993. V. 22. № 5. P. 329−339.
- Um S.H., Mulhall C., Alisa A., Ives A.R., Karani J., Williams R., Bertoletti A., Behboudi S. {alpha}-Fetoprotein Impairs APC Function and Induces Their Apoptosis. // J Immunol. 2004. V. 173. № 3. P. 1772−1778.
- Irony-Tur-Sinai M., Grigoriadis N., Lourbopoulos A., Pinto-Maaravi F., Abramsky O., Brenner T. Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. // Exp Neurol. 2006. V. 198. № 1. P. 136−144.
- Черешнев B.A., Родионов С. Ю. Черкасов В А, Малютина Н.Н., Орлов О. А. Альфа-фетопротеин. Екатеринбург: УрО РАН- 2004.
- Dudich Е. ММ-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases. // Curr Opin Mol Ther. 2007. V. 9. № 6. P. 603−610.
- Laderoute M.P., Pilarski L.M. The inhibition of apoptosis by alpha-fetoprotein (AFP) and the role of AFP receptors in anti-cellular senescence. // Anticancer Res. 1994. V. 14. № 6B. P. 2429−2438.
- Ohkawa K., Hatano T., Tsukada Y., Matsuda M. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro. // Br J Cancer. 1993. V. 67. № 2. P. 274−278.
- Lubgan D., Jozwiak Z., Grabenbauer G.G., Distel L.V. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells. // Cell Mol Biol Lett. 2009. V. 14. № 1. P. 113−127.
- Sarti D.A., Crandall B.F., Winter J., Robertson R.D., Kaback N.M., Karp L.E. Correlation of biparietal and fetal body diameters: 12—26 weeks gestation. // AJR. American journal of roentgenology. 1981. V. 137. № 1. P. 87−91.
- Dingemans A.C., van Ark-Otte J., Span S., Scagliotti G.V., van der Valk P., Postmus P.E., Giaccone G. Topoisomerase Ilalpha and other drug resistance markers in advanced non-small cell lung cancer. // Lung Cancer. 2001. V. 32. № 2. P. 117−128.
- Bass H.N., Sparkes R.S., Crandall B.F., Marcy S.M. Congenital contractural arachnodactyly, keratoconus, and probable Marfan syndrome in the same pedigree. // The Journal of pediatrics. 1981. V. 98. № 4. P. 591−593.
- Mohandas T., Crandall B.F., Sparkes R.S., Passage M.B., Sparkes M.C. Late replication studies in a human X/13 translocation: correlation with autosomal gene expression. // Cytogenetics and cell genetics. 1981. V. 29. № 4. P. 215−220.
- Uriel J., Villacampa M.J., Moro R., Naval J., Failly-Crepin C. Uptake of radiolabeled alpha-fetoprotein by mouse mammary carcinomas and its usefulness in tumor scintigraphy. // Cancer Res. 1984. V. 44. № 11. P. 5314−5319.
- Baba T., Damke H., Hinshaw J.E., Ikeda K., Schmid S.L., Warnock D.E. Role of dynamin in clathrin-coated vesicle formation. // Cold Spring Harbor symposia on quantitative biology. 1995. V. 60. P. 235−242.
- Uriel J., Poupon M.F., Geuskens M. Alphafoetoprotein uptake by cloned cell lines derived from a nickel-induced rat rhabdomyosarcoma. // Br J Cancer. 1983. V. 48. № 2. P. 261−269.
- Hajeri-Germond M., Naval J., Trojan J., Uriel J. The uptake of alpha-foetoprotein by C-1300 mouse neuroblastoma cells. // Br J Cancer. 1985. V. 51. № 6. P. 791−797.
- Villacampa M.J., Moro R., Naval J., Failly-Crepin C., Lampreave F., Uriel J. Alpha-fetoprotein receptors in a human breast cancer cell line. // Biochem Biophys Res Commun. 1984. V. 122. № 3. P. 1322−1327.
- Naval J., Villacampa M.J., Goguel A.F., Uriel J. Cell-type-specific receptors for alpha-fetoprotein in a mouse T-lymphoma cell line. // Proc Natl Acad Sci USA. 1985. V. 82. № 10. P. 3301−3305.
- Suzuki Y., Zeng C.Q., Alpert E. Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. // J Clin Invest. 1992. V. 90. № 4. P. 1530−1536.
- Esteban C., Geuskens M., Uriel J. Activation of an alpha-fetoprotein (AFP)/receptor autocrine loop in HT-29 human colon carcinoma cells. // Int J Cancer. 1991. V. 49. № 3. P. 425 430.
- Torres J.M., Laborda J., Naval J., Darracq N., Calvo M., Mishal Z., Uriel J. Expression of alpha-fetoprotein receptors by human T-lymphocytes during blastic transformation. // Mol Immunol. 1989. V. 26. № 9. P. 851−857.
- Biddle W., Sarcione E.J. Specific cytoplasmic alpha-fetoprotein binding protein in MCF-7 human breast cancer cells and primary breast cancer tissue. // Breast Cancer Res Treat. 1987. V. 10. № 3. P. 279−286.
- Mizejewski G.J. Alpha-fetoprotein binding proteins: implications for transmembrane passage and subcellular localization. // Life Sci. 1995. V. 56. № 1. P. 1−9.
- Moro R., Tamaoki T., Wegmann T.G., Longenecker B.M., Laderoute M.P. Monoclonal antibodies directed against a widespread oncofetal antigen: the alpha-fetoprotein receptor. // Tumour Biol. 1993. V. 14. № 2. P. 116−130.
- Kanevsky V., Pozdnyakova L.P., Aksenova O.A., Severin S.E., Katukov V., Severin E.S. Isolation and characterization of AFP-binding proteins from tumor and fetal human tissues. // Biochem Mol Biol Int. 1997. V. 41. № 6. P. 1143−1151.
- Alava M.A., Iturralde M., Lampreave F., Pineiro A. Specific uptake of alpha-fetoprotein and albumin by rat Morris 7777 hepatoma cells. // Tumour Biol. 1999. V. 20. № 1. P. 52−64.
- Mizejewski G.J., MacColl R. Alpha-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics. // Mol Cancer Ther. 2003. V. 2. № 11. P. 1243−1255.
- Mizejewski G.J., Dias J.A., Hauer C.R., Henrikson K.P., Gierthy J. Alpha-fetoprotein derived synthetic peptides: assay of an estrogen-modifying regulatory segment. // Mol Cell Endocrinol. 1996. V. 118. № 1−2. P. 15−23.
- Butterstein G.M., Mizejewski G.J. Alpha-fetoprotein inhibits frog metamorphosis: implications for protein motif conservation. // Comp Biochem Physiol A Mol Integr Physiol. 1999. V. 124. № 1. P. 39−45.
- Butterstein G., Morrison J., Mizejewski G.J. Effect of alpha-fetoprotein and derived peptides on insulin- and estrogen-induced fetotoxicity. // Fetal Diagn Ther. 2003. V. 18. № 5. P. 360−369.
- Eisele L.E., Mesfin F.B., Bennett J.A., Andersen T.T., Jacobson H.I., Soldwedel H., MacColl Pv., Mizejewski G.J. Studies on a growth-inhibitory peptide derived from alpha-fetoprotein and some analogs. // J Pept Res. 2001. V. 57. № 1. P. 29−38.
- Eisele L.E., Mesfin F.B., Bennett J.A., Andersen T.T., Jacobson H.I., Vakharia D.D., MacColl R., Mizejewski G.J. Studies on analogs of a peptide derived from alpha-fetoprotein having antigrowth properties. // J Pept Res. 2001. V. 57. № 6. P. 539−546.
- Mizejewski G.J., Butterstein G. Survey of functional activities of alpha-fetoprotein derived growth inhibitory peptides: review and prospects. // Curr Protein Pept Sci. 2006. V. 7. № 1. P. 73−100.
- Muehlemann M., Miller K.D., Dauphinee M., Mizejewski G.J. Review of Growth Inhibitory Peptide as a biotherapeutic agent for tumor growth, adhesion, and metastasis. // Cancer Metastasis Rev. 2005. V. 24. № 3. P. 441−467.
- Vakharia D., Mizejewski G.J. Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer. // Breast Cancer Res Treat. 2000. V. 63. № 1. P. 41−52.
- Maurin M., Garnuszek P., Karczmarczyk U., Mirowski M. Studies on 99mTc-labeling of the modified fragment of human alfa-fetoprotein (P149-QY). // Journal of Radioanalytical and Nuclear Chemistry. 2008. V. 275. № 1. P. 101−107.
- Linton K.J., Higgins C.F. The Escherichia coli ATP-binding cassette (ABC) proteins. // Mol Microbiol. 1998. V. 28. № 1. P. 5−13.
- Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. // Genome Res. 2001. V. 11. № 7. P. 1156−1166.
- Dean M., Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. // Annu Rev Genomics Hum Genet. 2005. V. 6. P. 123−142.
- Riordan J.R., Ling V. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability. // J Biol Chem. 1979. V. 254. № 24. P. 12 701−12 705.
- Rees D.C., Johnson E., Lewinson O. ABC transporters: the power to change. // Nat Rev Mol Cell Biol. 2009. V. 10. № 3. P. 218−227.
- Choi C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. // Cancer Cell Int. 2005. V. 5. P. 30.
- Deeley R.G., Westlake C., Cole S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. // Physiol Rev. 2006. V. 86. № 3. P. 849−899.
- Baker E.K., El-Osta A. MDR1, chemotherapy and chromatin remodeling. // Cancer Biol Ther. 2004. V. 3. № 9. P. 819−824.
- Labialle S., Gayet L., Marthinet E., Rigal D., Baggetto L.G. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. // Biochem Pharmacol. 2002. V. 64. № 5−6. P. 943−948.
- Breier A., Barancik M., Sulova Z., Uhrik B. P-glycoprotein—implications of metabolism of neoplastic cells and cancer therapy. // Curr Cancer Drug Targets. 2005. V. 5. № 6. P. 457−468.
- Doz F., Roosen N., Rosenblum M.L. Metallothionein and anticancer agents: the role of metallothionein in cancer chemotherapy. // J Neurooncol. 1993. V. 17. № 2. P. 123−129.
- Lazo J.S., Basu A. Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. // Semin Cancer Biol. 1991. V. 2. № 4. P. 267−271.
- Chen A.Y., Liu L.F. DNA topoisomerases: essential enzymes and lethal targets. // Annu Rev Pharmacol Toxicol. 1994. V. 34. P. 191−218.
- Makin G. Targeting apoptosis in cancer chemotherapy. // Expert Opin Ther Targets. 2002. V. 6. № 1. P. 73−84.
- Fan S., Smith M.L., Rivet D.J., 2nd, Duba D., Zhan Q., Kohn K.W., Fornace A.J., Jr.,
- П’РАППАГ /f nicrimti An nf fimptmn opnciti^ap Krooct ломлаг nolle +А Лionlnfmv/ X .1*1, i^iiJl U^/ЫЧ/И VI 1U11VUU11 JVllJiU^VJ l/l WUJl W14J.11/W1. X*A/1 / WHO IU WlOUlUlill ШШpentoxifylline. // Cancer Res. 1995. V. 55. № 8. P. 1649−1654.
- Sarkar R., Jain R.K., Puri P. Melasma in Indian males. // Dermatol Surg. 2003. V. 29. № 2. P. 204.
- Smith D.J., Ng H., Kluck R.M., Nagley P. The mitochondrial gateway to cell death. // IUBMB Life. 2008. V. 60. № 6. P. 383−389.
- Schwarz M., Andrade-Navarro M.A., Gross A. Mitochondrial carriers and pores: key regulators of the mitochondrial apoptotic program? // Apoptosis. 2007. V. 12. № 5. P. 869−876.
- Sekine I., Shimizu C., Nishio K., Saijo N., Tamura T. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. // Int J Clin Oncol. 2009. V. 14. № 2. P. 112−119.
- Kirkin V., Joos S., Zornig M. The role of Bcl-2 family members in tumorigenesis. // Biochim Biophys Acta. 2004. V. 1644. № 2−3. P. 229−249.
- Daidone M.G., Luisi A., Veneroni S., Benini E., Silvestrini R. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. // Endocr Relat Cancer. 1999. V. 6. № 1. P. 61−68.
- Adams J.M., Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. // Curr Opin Immunol. 2007. V. 19. № 5. P. 488−496.
- Wilds C.J., Maier M.A., Tereshko V., Manoharan M., Egli M. Direct observation of a cytosine analogue that forms five hydrogen bonds to guanosine: guanidino G-clamp. // Angew Chem Int Ed Engl. 2002. V. 41. № 1. P. 115−117.
- Cowling V.H., Cole M.D. Mechanism of transcriptional activation by the Myc oncoproteins. // Semin Cancer Biol. 2006. V. 16. № 4. P. 242−252.
- Ponzielli R., Katz S., Barsyte-Lovejoy D., Penn L.Z. Cancer therapeutics: targeting the dark side of Myc. // Eur J Cancer. 2005. V. 41. № 16. P. 2485−2501.
- Dominguez-Sola D., Ying C.Y., Grandori C., Ruggiero L., Chen B., Li M., Galloway D.A., Gu W., Gautier J., Dalla-Favera R. Non-transcriptional control of DNA replication by c-Myc. // Nature. 2007. V. 448. № 7152. P. 445−451.
- Spencer C.A., Groudine M. Control of c-myc regulation in normal and neoplastic cells. // Adv Cancer Res. 1991. V. 56. P. 1−48.
- Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. //Oncogene. 1999. V. 18. № 19. P. 3004−3016.
- Fukumura D., Ushiyama A., Duda D.G., Xu L., Tarn J., Krishna V., Chatterjee K., Garkavtsev I., Jain R.K. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. // Circ Res. 2003. V. 93. № 9. P. e88−97.
- Sears R.C. The life cycle of C-myc: from synthesis to degradation. // Cell Cycle. 2004. V. 3. № 9. P. 1133−1137.
- Izumi Y., di Tomaso E., Hooper A., Huang P., Huber J., Hicklin D.J., Fukumura D., Jain R.K., Suit H.D. Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts. // Cancer Res. 2003. V. 63. № 4. P. 747−751.
- Rapp U.R., Korn C., Ceteci F., Karreman C., Luetkenhaus K., Serafin V., Zanucco E., Castro I., Potapenko T. Myc Is a Metastasis Gene for Non-Small-Cell Lung Cancer. // PLoS One. 2009. V. 4. № 6. P. e6029.
- Ahmed F.E. Molecular markers that predict response to colon cancer therapy. // Expert Rev Mol Diagn. 2005. V. 5. № 3. P. 353−375.
- Butt A.J., McNeil C.M., Musgrove E.A., Sutherland R.L. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin Dl and cyclin E. // Endocr Relat Cancer. 2005. V. 12 Suppl 1. P. S47−59.
- Blackburn E.H. Telomeres: structure and synthesis. // J Biol Chem. 1990. V. 265. № 11. P. 5919−5921.
- Olovnikov A.M. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. // J Theor Biol. 1973. V. 41. № 1. P. 181−190.
- Wright W.E., Shay J.W. The two-stage mechanism controlling cellular senescence and immortalization. // Exp Gerontol. 1992. V. 27. № 4. P. 383−389.
- Rhodes D., Fairall L., Simonsson T., Court R., Chapman L. Telomere architecture. // EMBO Rep. 2002. V. 3. № 12. P. 1139−1145.
- Liu J.P. Studies of the molecular mechanisms in the regulation of telomerase activity. // FASEB J. 1999. V. 13. № 15. P. 2091−2104.
- Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., Dalla-Favera R. Direct activation of TERT transcription by c-MYC. // Nat Genet. 1999. V. 21. № 2. P. 220 224.
- Tian X., Chen B., Liu X. Telomere and telomerase as targets for cancer therapy. // Appl Biochem Biotechnol. V. 160. № 5. P. 1460−1472.
- Kang D.I., Kang H.K., Gwak H.S., Han H.K., Lim S.J. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells. // Drug Deliv. 2009. V. 16. № 5. P. 261−267.
- Michieli M., Damiani D., Ermacora A., Masolini P., Michelutti A., Michelutti T., Russo D., Pea F., Baccarani M. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. // Br J Haematol. 1999. V. 106. № 1. P. 92−99.
- Morinaga T., Sakai M., Wegmann T.G., Tamaoki T. Primary structures of human alpha-fetoprotein and its mRNA. // Proceedings of the National Academy of Sciences of the United States of America. 1983. V. 80. № 15. P. 4604−4608.
- Bogush T., Robert J. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells. // Anticancer Res. 1996. V. 16. № 1. P. 365−368.
- Cartier R., Reszka R. Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems. // Gene Ther. 2002. V. 9. № 3. P. 157−167.
- Collas P., Alestrom P. Nuclear localization signals: a driving force for nuclear transport of plasmid DNA in zebrafish. // Biochem Cell Biol. 1997. V. 75. № 5. P. 633−640.
- Bremner K.H., Seymour L.W., Logan A., Read ML. Factors influencing the Ability of Nuclear Localization Sequence Peptides To Enhance Nonviral Gene Delivery. // Bioconjugate Chemistry. 2003. V. 15. № 1. P. 152−161.
- Prakash T.P., Kawasaki A.M., Fraser A.S., Vasquez G., Manoharan M. Synthesis of 2'-0−2-[(N, N-dimethylamino)oxy.ethyl] modified nucleosides and oligonucleotides. // J Org Chem. 2002. V. 67. № 2. P. 357−369.
- Fritzer M., Szekeres T., Szuts V., Jarayam H.N., Goldenberg H. Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. // Biochem Pharmacol. 1996. V. 51. № 4. P. 489−493.
- Lemieux P., Page M. Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate. // Anticancer Res. 1994. V. 14. № 2A. P. 397−403.
- Garmann D., Warnecke A., Kalayda G.V., Kratz F., Jaehde U. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. // J Control Release. 2008. V. 131. № 2. P. 100−106.
- Sheldon K., Marks A., Baumal R. Sensitivity of multidrug resistant KB-C1 cells to an antibody-dextran-adriamycin conjugate. // Anticancer Res. 1989. V. 9. № 3. P. 637−641.
- Chitambar C.R. Gallium compounds as antineoplastic agents. // Curr Opin Oncol. 2004. V. 16. № 6. P. 547−552.
- Ehrlich P. The partial function of cells. (Nobel Prize address given on 11 December 1908 at Stockholm). // Int Arch Allergy Appl Immunol. 1954. V. 5. № 2. P. 67−86.
- Butcher E.C., Weissman I.L. Direct fluorescent labeling of cells with fluorescein or rhodamine isothiocyanate. I. Technical aspects. // J Immunol Methods. 1980. V. 37. № 2. P. 97 108.
- Le Bouteiller P.P., Mishal Z., Lemonnier F.A., Kourilsky F.M. Quantification by flow cytofluorimetry of HLA class I molecules at the surface of murine cells transformed by cloned HLA genes. // J Immunol Methods. 1983. V. 61. № 3. P. 301−315.
- Fenton C., Perry C.M. Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia. // BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2006. V. 20. № 2. P. 137−139.
- Torres J.M., Geuskens M., Uriel J. Receptor-mediated endocytosis and recycling of alpha-fetoprotein in human B-lymphoma and T-leukemia cells. // Int J Cancer. 1991. V. 47. № 1. P. 110−117.
- Esteban C., Trojan J., Macho A., Mishal Z., Lafarge-Frayssinet C., Uriel J. Activation of an alpha-fetoprotein/receptor pathway in human normal and malignant peripheral blood mononuclear cells. // Leukemia. 1993. V. 7. № 11. P. 1807−1816.
- Biaglow J.E., Miller R.A. The thioredoxin reductase/thioredoxin system: novel redox targets for cancer therapy. // Cancer Biol Ther. 2005. V. 4. № 1. P. 6−13.
- Arunachalam В., Phan U.T., Geuze H.J., Cresswell P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). // Proc Natl Acad Sci USA. 2000. V. 97. № 2. P. 745−750.
- Kooistra Т., Millard P.C., Lloyd J.B. Role of thiols in degradation of proteins by cathepsins. // Biochem J. 1982. V. 204. № 2. P. 471−477.
- Feener E.P., Shen W.C., Ryser H.J. Cleavage of disulfide bonds in endocytosed macromolecules. A processing not associated with lysosomes or endosomes. // J Biol Chem.1qqh v p 18 780−1878sx у у V/. т • ^ ¦ v ←л. • л. «x w I vy v x v f w •
- Bennett J.A., Semeniuk D.J., Jacobson H.I., Murgita R.A. Similarity between natural and recombinant human alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth. // Breast Cancer Res Treat. 1997. V. 45. № 2. P. 169−179.
- DiMarco A. Adriamycin (NSC-123 127): mode and mechanism of action. // Cancer Chemother. Rep. 1975. V. 6. P. 91−106.
- Hamza A., Sarma M.H., Sarma R.H. Plausible interaction of an alpha-fetoprotein cyclopeptide with the G-protein-coupled receptor model GPR30: docking study by molecular dynamics simulated annealing. // J Biomol Struct Dyn. 2003. V. 20. № 6. P. 751−758.
- Tan W., Loke Y.H., Stein C.A., Miller P., Colombini M. Phosphorothioate oligonucleotides block the VDAC channel. // Biophys J. 2007. V. 93. № 4. P. 1184−1191.
- Lai J.C., Tan W., Benimetskaya L., Miller P., Colombini M., Stein C.A. A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC. // Proc Natl Acad Sci U S A. 2006. V. 103. № 19. P. 7494−7499.
- Tan W., Lai J.C., Miller P., Stein C.A., Colombini M. Phosphorothioate oligonucleotides reduce mitochondrial outer membrane permeability to ADP. // Am J Physiol Cell Physiol. 2007. V. 292. № 4. P. C1388−1397.
- Carpenter G., Cohen S. Epidermal growth factor. // Annu Rev Biochem. 1979. V. 48. P. 193−216.
- Saeki Т., Takashima S., Tachibana М., Koga М., Hiyama Е., Salomon D.S., Holland J.F., Ohnuma Т. Inhibitory effect of telomere-mimic phosphorothioate oligodeoxy nucleotides (S-ODNS) on human tumor cell lines. // Oncology. 1999. V. 57 Suppl 2. P. 27−36.
- Page T.J., Mata J.E., Bridge J.A., Siebler J.C., Neff J.R., Iversen P.L. The cytotoxic effects of single-stranded telomere mimics on OMA-BL1 cells. // Exp Cell Res. 1999. V. 252. № 1. P. 41−49.
- Berkers J.A., van Bergen en Henegouwen P.M., Boonstra J. Three classes of epidermal growth factor receptors on HeLa cells. // J Biol Chem. 1991. V. 266. № 2. P. 922−927.
- Kroning R., Jones J.A., Horn D.K., Chuang C.C., Sanga R., Los G., Howell S.B., Christen R.D. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. // Br J Cancer. 1995. V. 72. № 3. P. 615−619.
- Blackburn E.H., Chan S., Chang J., Fulton T.B., Krauskopf A., McEachern M., Prescott J., Roy J., Smith C., Wang H. Molecular manifestations and molecular determinants of telomere capping. // Cold Spring Harb Symp Quant Biol. 2000. V. 65. P. 253−263.
- Collas P., Alestrom P. Nuclear localization signals enhance germline transmission of a transgene in zebrafish. // Transgenic Res. 1998. V. 7. № 4. P. 303−309.
- Morris M.C., Vidal P., Chaloin L., Heitz F., Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. // Nucleic Acids Res. 1997. V. 25. № 14. P. 2730−2736.
- Sinha B.K., Politi P.M. Anthracyclines. // Cancer Chemother Biol Response Modif. 1990. V. 11. P. 45−57.
- Long B.H., Golik J., Forenza S., Ward B., Rehfuss R., Dabrowiak J.C., Catino J.J., Musial S.T., Brookshire K.W., Doyle T.W. Esperamicins, a class of potent antitumor antibiotics: mechanism of action. // Proc Natl Acad Sci USA. 1989. V. 86. № 1. P. 2−6.
- Kaneta Y., Tsukazaki K., Kubushiro K., Sakayori M., Ueda M., Nozawa S. Selective cytotoxicity of adriamycin immunoconjugate of monoclonal antibody MSN-1 to endometrial adenocarcinoma in vitro and in vivo. // Oncol Rep. 2000. V. 7. № 5. P. 1099−1106.
- Jinno H., Ueda M., Enomoto K., Ikeda T., Kyriakos P., Kitajima M. Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines. // Surg Today. 1996. V. 26. № 7. P. 501−507.
- Yamamoto K., Acton E.M., Henry D.W. Antitumor activity of some derivatives of daunorubicin at the amino and methyl ketone functions. // Journal of Medicinal Chemistry. 2002. V. 15. № 8. P. 872−875.
- Arnon R., Sela M. In vitro and in vivo efficacy of conjugates of daunomycin with antitumor antibodies. // Immunol Rev. 1982. V. 62. P. 5−27.
- Hurwitz E., Levy R., Maron R., Wilchek M., Arnon R., Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. // Cancer Res. 1975. V. 35. № 5. P. 1175−1181.
- Biroccio A., Leonetti C., Zupi G. The future of antisense therapy: combination with anticancer treatments. // Oncogene. 2003. V. 22. № 42. P. 6579−6588.